Toxikon Corp. has completed toxicity studies in two species for Cellceutix Corp.’s Kevetrin, a compound in development for the treatment of resistant lung and breast cancers.
Toxikon Corp. has expanded its immunotoxicology offerings, adding flow cyctometry, which enables the direct analysis of cells to detect a variety of specifically labeled components.